Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
7.09(c) 6.89(c) 6.7(c) 6.66(c) 6.74 Last
47 287 117 128 108 260 149 472 69 548 Volume
-1.25% -2.82% -2.76% -0.60% +1.20% Change
More quotes
Financials
Sales 2020 35,0 M 39,6 M 39,6 M
Net income 2020 -31,4 M -35,6 M -35,6 M
Net cash position 2020 3,70 M 4,19 M 4,19 M
P/E ratio 2020 -7,09x
Yield 2020 -
Sales 2021 82,0 M 92,9 M 92,9 M
Net income 2021 -12,4 M -14,1 M -14,1 M
Net cash position 2021 17,8 M 20,2 M 20,2 M
P/E ratio 2021 -15,3x
Yield 2021 -
Capitalization 189 M 214 M 214 M
EV / Sales 2020 5,30x
EV / Sales 2021 2,09x
Nbr of Employees 47
Free-Float 81,9%
More Financials
Company
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes. At the end of 2019, the group had a portfolio of 3 products in clinical development, including 1 in Phase III (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 3 in phase II (PXL770, PXL065 and PXL007 for the treatment of... 
More about the company
Surperformance© ratings of Poxel
Trading Rating : Investor Rating : -
More Ratings
Latest news on POXEL
07/07POXEL : Corporate Presentation - English
PU
06/25POXEL : Announces Results from June 24, 2020 Ordinary Annual and Extraordinary G..
BU
06/25POXEL : Announces Positive Pharmacokinetic Pharmacodynamic Study Results for PXL..
AQ
06/24POXEL : Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Res..
BU
05/28POXEL : Announces Participation in Upcoming Virtual Investor Conferences
BU
05/26Poxel Successfully Raises EUR17.7 Million in a Capital Increase
AQ
05/25POXEL : Announces Program Update and Preclinical Results on PXL770 for NASH Comb..
BU
05/25POXEL : Successfully Raises €17.7 Million in a Capital Increase
BU
05/18POXEL : Announces Notice of its Annual General Meeting to be Held on June 24, 20..
BU
05/18POXEL : Mixed general shareholder meeting
CO
04/21POXEL : Announces First Quarter 2020 Financial and Corporate Update
BU
04/21POXEL : 1st quarter earnings
CO
04/20POXEL : Announces Publication of Imeglimin Clinical Study Results in Clinical Ph..
BU
04/20POXEL : Announces Availability of 2019 Universal Registration Document and Provi..
BU
03/26POXEL : Reports Financial Results for Full Year 2019 and Provides Corporate Upda..
BU
More news
News in other languages on POXEL
07/07POXEL : Bilan semestriel du contrat de liquidité contracté avec ODDO Corporate F..
07/07POXEL : Bilan semestriel du contrat de liquidité contracté avec ODDO Corporate F..
07/07POXEL : Corporate Presentation - English
06/25POXEL : Announces Results from June 24, 2020 Ordinary Annual and Extraordinary G..
06/25POXEL : annonce les résultats de son Assemblée générale ordinaire annuelle et ex..
More news
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 17,60 €
Last Close Price 6,66 €
Spread / Highest target 215%
Spread / Average Target 164%
Spread / Lowest Target 106%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-45.41%214
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955